Aerska Therapeutics vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzheimer's and Parkinson's. Non-viral CNS delivery crossing blood-brain barrier.
About
Aerska Therapeutics is developing a brain-shuttle RNAi (RNA interference) platform for CNS gene silencing — specifically targeting the genetic forms of Alzheimer's disease and Parkinson's disease caused by dominant mutations that can be silenced by RNA therapeutics. The company raised $39 million in February 2026, doubling its prior $21 million Series A round, led by ex-AstraZeneca neuroscience executives who validated both the science and the commercial opportunity.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.